LENZ Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
LENZ Therapeutics Stock-Based Compensation Growth & History (LENZ)
LENZ Therapeutics's stock-based compensation was $12.5M for fiscal 2025.
View full LENZ Therapeutics company overviewLENZ Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.5M | $6.2M | +97.12% |
| 2024 | 2024-12-31 | $6.4M | $5.0M | +373.94% |
| 2023 | 2023-12-31 | $1.3M | −$12.2M | −90.08% |
| 2022 | 2022-12-31 | $13.5M | $5.7M | +71.95% |
| 2021 | 2021-12-31 | $7.9M | $7.7M | +4346.89% |
| 2020 | 2020-12-31 | $177,000 | — | — |
LENZ Therapeutics quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.5M | $1.6M | +57.19% |
| Q1 2026 | 2026-03-31 | $4.3M | $1.8M | +69.04% |
| Q4 2025 | 2025-12-31 | $3.7M | $2.0M | +125.64% |
| Q3 2025 | 2025-09-30 | $3.5M | $1.3M | +58.33% |
| Q2 2025 | 2025-06-30 | $2.8M | $1.2M | +78.15% |
| Q1 2025 | 2025-03-31 | $2.6M | $1.6M | +169.80% |
| Q4 2024 | 2024-12-31 | $1.6M | $1.1M | +214.67% |
| Q3 2024 | 2024-09-30 | $2.2M | $1.7M | +343.52% |
| Q2 2024 | 2024-06-30 | $1.6M | $1.4M | +744.97% |
| Q1 2024 | 2024-03-31 | $947,000 | $805,000 | +566.90% |
| Q4 2023 | 2023-12-31 | $518,000 | −$3.1M | −85.70% |
| Q3 2023 | 2023-09-30 | $494,000 | −$2.7M | −84.61% |
| Q2 2023 | 2023-06-30 | $189,000 | −$3.2M | −94.38% |
| Q1 2023 | 2023-03-31 | $142,000 | −$3.2M | −95.75% |
| Q4 2022 | 2022-12-31 | $3.6M | $1.2M | +48.08% |
| Q3 2022 | 2022-09-30 | $3.2M | $836,000 | +35.21% |
| Q2 2022 | 2022-06-30 | $3.4M | $1.3M | +66.50% |
| Q1 2022 | 2022-03-31 | $3.3M | $2.3M | +223.52% |
| Q4 2021 | 2021-12-31 | $2.4M | — | — |
| Q3 2021 | 2021-09-30 | $2.4M | $2.3M | +6494.44% |
| Q2 2021 | 2021-06-30 | $2.0M | $2.0M | +201700.00% |
| Q1 2021 | 2021-03-31 | $1.0M | — | — |
| Q3 2020 | 2020-09-30 | $36,000 | — | — |
| Q2 2020 | 2020-06-30 | $1,000 | — | — |
LENZ Therapeutics stock-based compensation trends
Over the last five fiscal years, LENZ Therapeutics's stock-based compensation increased from $177,000 to $12.5M, a change of $12.4M. The latest reported quarter, Q2 2026, shows $4.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review LENZ Therapeutics source filings ↗